PT - JOURNAL ARTICLE AU - M Rajagopal Padma AU - Prameela Dinesh AU - Rajesh Sundaresan AU - Siva Athreya AU - Shilpa Shiju AU - Parimala S Maroor AU - R Lalitha Hande AU - Jawaid Akhtar AU - Trilok Chandra AU - Deepa Ravi AU - Eunice Lobo AU - Yamuna Ana AU - Prafulla Shriyan AU - Anita Desai AU - Ambica Rangaiah AU - Ashok Munivenkatappa AU - S Krishna AU - Shantala Gowdara Basawarajappa AU - HG Sreedhara AU - KC Siddesh AU - B Amrutha Kumari AU - Nawaz Umar AU - BA Mythri AU - KM Mythri AU - Mysore Kalappa Sudarshan AU - Ravi Vasanthapuram AU - Giridhara R Babu TI - Second round statewide survey for estimation of the burden of active infection and anti-SARS-CoV-2 IgG antibodies in the general population of Karnataka, India AID - 10.1101/2021.08.10.21261842 DP - 2021 Jan 01 TA - medRxiv PG - 2021.08.10.21261842 4099 - http://medrxiv.org/content/early/2021/08/11/2021.08.10.21261842.short 4100 - http://medrxiv.org/content/early/2021/08/11/2021.08.10.21261842.full AB - Objective The second round of the serial cross-sectional sentinel-based population survey to assess active infection, seroprevalence, and their evolution in the general population across Karnataka was conducted. Additionally, a longitudinal study among participants identified as COVID-19 positive in the first survey round was conducted to assess the clinical sensitivity of the testing kit used.Methods The cross-sectional study of 41,228 participants across 290 healthcare facilities in all 30 districts of Karnataka was done among three groups of participants (low, moderate, and high-risk). Consenting participants were subjected to real-time reverse transcription-polymerase chain reaction (RT-PCR) testing, and antibody (IgG) testing.Results Overall weighted adjusted seroprevalence of IgG was 15.6% (95% CI: 14.9–16.3), crude IgG prevalence was 15.0% and crude active prevalence was 0.5%. Statewide infection fatality rate (IFR) was estimated as 0.11%, and COVID-19 burden estimated between 26.1 to 37.7% (at 90% confidence). Clinical sensitivity of the IgG ELISA test kit was estimated as ≥38.9%.Conclusion The sentinel-based population survey helped identify districts that needed better testing, reporting, and clinical management. The state was far from attaining natural immunity during the survey and hence must step up vaccination coverage and enforce public health measures to prevent the spread of COVD-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was supported by the National Health Mission, Karnataka. Directorate of H&FW and Directorate of Medical Education supported by contributing their testing and computing equipment. Dr Giridhara R Babu was supported by the Wellcome Trust/DBT India Alliance Fellowship [Grant number: IA/CPHI/14/1/501499], Dr Siva R. Athreya was supported by the SERB MATRICS grant and Dr Rajesh Sundaresan was supported by the grant given by Centre for Networked Intelligence (Indian Institute of Science). The funders of the study had no role in the study design, data collection, data analysis, data interpretation, or the writing of the report. They did not participate in the decision to submit the manuscript for publication. The principal investigator (MRP) and key investigators had full access to the data. The corresponding author (GRB) had final responsibility for the decision to submit for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Ethics Committee (IEC) of the Indian Institute of Public Health Bengaluru campus reviewed and approved the study (vide. IIPHHB/TRCIEC/174/2020) and the subsequent change of protocol to perform the longitudinal study (vide PHFI/IIPH BLR/076/2020 21). We informed the participants of the purpose of the surveys, how the samples would be taken and requested them to respond to the screening questions. After obtaining informed consent, we noted basic demographic details, exposure history, symptoms observed in the previous month, and clinical history. Participants test results were shared with them by the concerned healthcare facility.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data are accessible to researchers upon formal request for data addressed to the Commissioner, Health and Family Welfare Services, Government of Karnataka.